Pfizer’s Braftovi to command 42 per cent share of BRAF inhibitors melanoma market by 2028:…
GlobalData’s patient-based forecast reveals that the BRAF inhibitor market for melanoma will reach a key milestone by 2028, with…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Zelboraf
Roche gets US FDA approval for Tecentriq combo to treat advanced melanoma
The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf…
Roche’s Tecentriq cocktail scores trial success in melanoma
The study met its primary aim of showing progression-free survival in patients with previously untreated BRAF V600…